Trial comparisons

curl "https://conductscience.org/api/comparisons/v1?page=95"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=95

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02499679-f8678195",
        "title": "MACE Events Within 90 Days Subject Whose FFRCT Was >0.80 vs MACE Events Within 90 Days. Patients With at Least One FFRCT Value ≤ 0.80: Percentage of Major Adverse Coronary Events (MACE) at 90 Days",
        "summary": "0 of 1592 against 19 of 3145; risk difference -0.6 points, 95% interval -0.9 to -0.3; NCT02499679, Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care",
        "record": "/library/comparisons/NCT02499679-f8678195",
        "nct_id": "NCT02499679",
        "kind": "outcome",
        "participants": 4737,
        "risk_difference": {
          "value": -0.006041335453100159,
          "lower": -0.009416812924593985,
          "upper": -0.002800273844722289
        },
        "group_1": "0 of 1,592",
        "group_2": "19 of 3,145",
        "difference": "-0.6 points",
        "interval": "-0.9 to -0.3",
        "trial_title": "Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care"
      },
      {
        "id": "NCT03036124-deaths",
        "title": "Dapa 10mg vs Placebo: deaths from any cause",
        "summary": "286 of 2368 against 333 of 2368; risk difference -2.0 points, 95% interval -3.9 to -0.1; NCT03036124, Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure",
        "record": "/library/comparisons/NCT03036124-deaths",
        "nct_id": "NCT03036124",
        "kind": "deaths",
        "participants": 4736,
        "risk_difference": {
          "value": -0.01984797297297297,
          "lower": -0.03906568896172795,
          "upper": -0.000639261112046513
        },
        "group_1": "286 of 2,368",
        "group_2": "333 of 2,368",
        "difference": "-2.0 points",
        "interval": "-3.9 to -0.1",
        "trial_title": "Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=96",
  "request_id": "YRhv6HrmTKXlkiZa"
}